Boehringer Ingelheim licenses Cue Biopharma's CUE-501 bispecific antibody for $12M upfront, $345M in milestones to target autoimmune diseases via B cell depletion.

The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the ...

Myeloid Therapeutics, a company developing in vivo cell therapies for cancer as well as a novel gene editing technology, has ...

Ab­b­Vie and San­doz have re­solved their patent dis­pute over Ab­b­Vie’s block­buster im­munol­o­gy drug Rin­voq. San­doz ...

A panel of experts who decide the national immunization schedule will meet on Tuesday for the first time in 2025, providing ...

The American Medical Association is urging Optum, a unit of UnitedHealth Group, to ease up on recouping the loans it provided ...

In a development landscape as extensive as obesity, we think Pfizer could be better served by looking outside,' Stifel ...

Boston and Dublin biotech Mural Oncology is laying off nearly all of its employees and ending clinical development of its IL-2 drug nemvaleukin alfa.

Sanofi's amlitelimab fails Phase 2 asthma trial at highest dose, but company sees path forward based on medium dose results in specific patient subgroup ...

Attovia Therapeutics is turning fundraising announcements into an annual tradition. In June 2023, the San Carlos, CA-based startup launched with $60 million. Then in May 2024 ...

Johnson & Johnson is maintaining its 2025 financial guidance and raising its sales forecast despite President Donald Trump’s efforts to tariff pharmaceuticals.

Tariffs on pharmaceutical products that President Donald Trump has teased for weeks are one step closer to fruition after the Department of Commerce confirmed it's launched an investigation into the ...